![Stefan Degenhardt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stefan Degenhardt is currently the Chief Executive Officer at Ventaleon GmbH since 2018.
Prior to this, he worked as the Chief Financial Officer at Vectura GmbH and as the Head of Finance & Business Administration at Pierrel Research Onco-Immunology GmbH.
| Sociétés | Poste | Fin |
|---|---|---|
Pierrel Research Onco-Immunology GmbH | Directeur Financier/CFO | - |
Ventaleon GmbH
 Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Engages in the research, development, manufacture, and distribution of antiviral substances and treatments taken by inhalation | Directeur Général | - |
Vectura GmbH
 Vectura GmbH Miscellaneous Commercial ServicesCommercial Services Develops and manufactures aerosol inhalation systems | Directeur Financier/CFO | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 3 |
|---|---|
Vectura GmbH
Vectura GmbH Miscellaneous Commercial ServicesCommercial Services Develops and manufactures aerosol inhalation systems | Commercial Services |
Pierrel Research Onco-Immunology GmbH | |
Ventaleon GmbH
Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Engages in the research, development, manufacture, and distribution of antiviral substances and treatments taken by inhalation | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
